Publication
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (8)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 8
- cancerCutaneous Melanomacbioportal_study1.00
- cancerMelanomacivic_curation1.00
- drugDabrafenibcivic_curation1.00
- drugVemurafenibcivic_curation1.00
- geneMAP2K2civic_curation1.00
- variantMAP2K2 C125Scivic_curation1.00
- variantMAP2K2 L46Fcivic_curation1.00
- variantMAP2K2 N126Dcivic_curation1.00
Curated evidence
Evidence citing this paper (14)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 24265153
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| HOXD8 mutation1 | ||||||||
| Dabrafenib + VemurafenibSubstitutes | Melanoma | Predictive | C | Supports Resistance | 2 | submitted | EID7670In a retrospective study, resistance mechanisms to BRAF inhibitor such as vemurafenib or dabrafenib in patients with BRAF V600 mutated melanoma were evaluated. A nonsense mutation in the HOXD8 gene wa… (full text at CIViC) PMID 24265153 · Van Allen et al., 2014 · Open in CIViC | civic |
| MAP2K1 F53Y1 | ||||||||
| Dabrafenib + VemurafenibSubstitutes | Melanoma | Predictive | C | Does Not Support Resistance | 4 | submitted | EID7663In a retrospective study, resistance mechanisms to BRAF inhibitor such as vemurafenib or dabrafenib in patients with BRAF V600 mutated melanoma were evaluated Five MAP2K1 gene mutations (encodes the M… (full text at CIViC) PMID 24265153 · Van Allen et al., 2014 · Open in CIViC | civic |
| MAP2K1 G128V1 | ||||||||
| Dabrafenib + VemurafenibSubstitutes | Melanoma | Predictive | C | Supports Resistance | 4 | submitted | EID7658In a retrospective study, resistance mechanisms to BRAF inhibitor such as vemurafenib or dabrafenib in patients with BRAF V600 mutated melanoma were evaluated Five MAP2K1 gene mutations (encodes the M… (full text at CIViC) PMID 24265153 · Van Allen et al., 2014 · Open in CIViC | civic |
| MAP2K1 G276W1 | ||||||||
| Dabrafenib + VemurafenibSubstitutes | Melanoma | Predictive | C | Does Not Support Resistance | 4 | submitted | EID7662In a retrospective study, resistance mechanisms to BRAF inhibitor such as vemurafenib or dabrafenib in patients with BRAF V600 mutated melanoma were evaluated Five MAP2K1 gene mutations (encodes the M… (full text at CIViC) PMID 24265153 · Van Allen et al., 2014 · Open in CIViC | civic |
| MAP2K1 P124L1 | ||||||||
| Dabrafenib + VemurafenibSubstitutes | Melanoma | Predictive | C | Supports Resistance | 4 | submitted | EID7661In a retrospective study, resistance mechanisms to BRAF inhibitor such as vemurafenib or dabrafenib in patients with BRAF V600 mutated melanoma were evaluated Five MAP2K1 gene mutations (encodes the M… (full text at CIViC) PMID 24265153 · Van Allen et al., 2014 · Open in CIViC | civic |
| MAP2K1 P124S1 | ||||||||
| Dabrafenib + VemurafenibSubstitutes | Melanoma | Predictive | C | Supports Resistance | 4 | submitted | EID7660In a retrospective study, resistance mechanisms to BRAF inhibitor such as vemurafenib or dabrafenib in patients with BRAF V600 mutated melanoma were evaluated Five MAP2K1 gene mutations (encodes the M… (full text at CIViC) PMID 24265153 · Van Allen et al., 2014 · Open in CIViC | civic |
| MAP2K1 V154I1 | ||||||||
| Dabrafenib + VemurafenibSubstitutes | Melanoma | Predictive | C | Supports Resistance | 4 | submitted | EID7659In a retrospective study, resistance mechanisms to BRAF inhibitor such as vemurafenib or dabrafenib in patients with BRAF V600 mutated melanoma were evaluated Five MAP2K1 gene mutations (encodes the M… (full text at CIViC) PMID 24265153 · Van Allen et al., 2014 · Open in CIViC | civic |
| MAP2K1 V60E1 | ||||||||
| Dabrafenib + VemurafenibSubstitutes | Melanoma | Predictive | C | Supports Resistance | 4 | submitted | EID7657In a retrospective study, resistance mechanisms to BRAF inhibitor such as vemurafenib or dabrafenib in patients with BRAF V600 mutated melanoma were evaluated Five MAP2K1 gene mutations (encodes the M… (full text at CIViC) PMID 24265153 · Van Allen et al., 2014 · Open in CIViC | civic |
| MAP2K2 C125S1 | ||||||||
| Dabrafenib + VemurafenibSubstitutes | Melanoma | Predictive | D | Supports Resistance | 4 | accepted | EID7664In a retrospective study, resistance mechanisms to BRAF inhibitor such as vemurafenib or dabrafenib in patients with BRAF V600 mutated melanoma were evaluated. Four mutations involving the MAP2K2 gene… (full text at CIViC) PMID 24265153 · Van Allen et al., 2014 · Open in CIViC | civic |
| MAP2K2 L46F1 | ||||||||
| Dabrafenib + VemurafenibSubstitutes | Melanoma | Predictive | D | Supports Resistance | 3 | accepted | EID7666In a retrospective study, resistance mechanisms to BRAF inhibitor such as vemurafenib or dabrafenib in patients with BRAF V600 mutated melanoma were evaluated. Four mutations involving the MAP2K2 gene… (full text at CIViC) PMID 24265153 · Van Allen et al., 2014 · Open in CIViC | civic |
| MAP2K2 N126D1 | ||||||||
| Dabrafenib + VemurafenibSubstitutes | Melanoma | Predictive | D | Supports Resistance | 3 | accepted | EID7667In a retrospective study, resistance mechanisms to BRAF inhibitor such as vemurafenib or dabrafenib in patients with BRAF V600 mutated melanoma were evaluated. Four mutations involving the MAP2K2 gene… (full text at CIViC) PMID 24265153 · Van Allen et al., 2014 · Open in CIViC | civic |
| MAP2K2 V35M1 | ||||||||
| Dabrafenib + VemurafenibSubstitutes | Melanoma | Predictive | C | Supports Resistance | 3 | submitted | EID7665In a retrospective study, resistance mechanisms to BRAF inhibitor such as vemurafenib or dabrafenib in patients with BRAF V600 mutated melanoma were evaluated. Four mutations involving the MAP2K2 gene… (full text at CIViC) PMID 24265153 · Van Allen et al., 2014 · Open in CIViC | civic |
| MITF Amplification1 | ||||||||
| Dabrafenib + VemurafenibSubstitutes | Melanoma | Predictive | C | Supports Resistance | 4 | submitted | EID7668In a retrospective study, resistance mechanisms to BRAF inhibitor such as vemurafenib or dabrafenib in patients with BRAF V600 mutated melanoma were evaluated. In one patient relapse-associated focal … (full text at CIViC) PMID 24265153 · Van Allen et al., 2014 · Open in CIViC | civic |
| RAC1 P29S1 | ||||||||
| Dabrafenib + VemurafenibSubstitutes | Melanoma | Predictive | B | Supports Resistance | 3 | submitted | EID7669In a retrospective study, resistance mechanisms to BRAF inhibitor such as vemurafenib or dabrafenib in patients with BRAF V600 mutated melanoma were evaluated. Among the 14 patients exhibiting early d… (full text at CIViC) PMID 24265153 · Van Allen et al., 2014 · Open in CIViC | civic |